184 related articles for article (PubMed ID: 31953902)
41. Interaction of human immunodeficiency virus type 1 and human herpesvirus type 8 infections on the incidence of Kaposi's sarcoma.
Jacobson LP; Jenkins FJ; Springer G; Muñoz A; Shah KV; Phair J; Zhang Z; Armenian H
J Infect Dis; 2000 Jun; 181(6):1940-9. PubMed ID: 10837173
[TBL] [Abstract][Full Text] [Related]
42. Kaposi Sarcoma in HIV-positive Solid-Organ Transplant Recipients: A French Multicentric National Study and Literature Review.
Charpentier C; Delyon J; Glotz D; Peraldi MN; Rerolle JP; Barrou B; Ducroux E; Coilly A; Legeai C; Barete S; Lebbé C
Transplantation; 2019 Jan; 103(1):e22-e28. PubMed ID: 30273235
[TBL] [Abstract][Full Text] [Related]
43. Prospective study of the effects of antiretroviral therapy on Kaposi sarcoma--associated herpesvirus infection in patients with and without Kaposi sarcoma.
Gill J; Bourboulia D; Wilkinson J; Hayes P; Cope A; Marcelin AG; Calvez V; Gotch F; Boshoff C; Gazzard B
J Acquir Immune Defic Syndr; 2002 Dec; 31(4):384-90. PubMed ID: 12447008
[TBL] [Abstract][Full Text] [Related]
44. Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases.
Rezza G; Andreoni M; Dorrucci M; Pezzotti P; Monini P; Zerboni R; Salassa B; Colangeli V; Sarmati L; Nicastri E; Barbanera M; Pristerà R; Aiuti F; Ortona L; Ensoli B
J Natl Cancer Inst; 1999 Sep; 91(17):1468-74. PubMed ID: 10469747
[TBL] [Abstract][Full Text] [Related]
45. Predictive Value of Serum Biomarkers for Response of Limited-Stage AIDS-Associated Kaposi Sarcoma to Antiretroviral Therapy With or Without Concomitant Chemotherapy in Resource-Limited Settings.
Epeldegui M; Chang D; Lee J; Magpantay LI; Borok M; Bukuru A; Busakhala N; Godfrey C; Hosseinipour MC; Kang M; Kanyama C; Langat D; Mngqibisa R; Mwelase N; Nyirenda M; Samaneka W; Hoagland B; Campbell TB; Martínez-Maza O; Krown SE;
J Acquir Immune Defic Syndr; 2023 Oct; 94(2):165-173. PubMed ID: 37368929
[TBL] [Abstract][Full Text] [Related]
46. Risk factors for Kaposi's sarcoma in HIV-positive subjects in Uganda.
Ziegler JL; Newton R; Katongole-Mbidde E; Mbulataiye S; De Cock K; Wabinga H; Mugerwa J; Katabira E; Jaffe H; Parkin DM; Reeves G; Weiss R; Beral V
AIDS; 1997 Nov; 11(13):1619-26. PubMed ID: 9365767
[TBL] [Abstract][Full Text] [Related]
47. Detection of Kaposi's sarcoma-associated herpesvirus in peripheral blood cells in human immunodeficiency virus infection: association with Kaposi's sarcoma, CD4 cell count, and HIV RNA levels.
Min J; Katzenstein DA
AIDS Res Hum Retroviruses; 1999 Jan; 15(1):51-5. PubMed ID: 10024052
[TBL] [Abstract][Full Text] [Related]
48. Burden of Kaposi sarcoma according to HIV status: A systematic review and global analysis.
Ibrahim Khalil A; Franceschi S; de Martel C; Bray F; Clifford GM
Int J Cancer; 2022 Jun; 150(12):1948-1957. PubMed ID: 35085400
[TBL] [Abstract][Full Text] [Related]
49. Similar Immunological Profiles Between African Endemic and Human Immunodeficiency Virus Type 1-Associated Epidemic Kaposi Sarcoma (KS) Patients Reveal the Primary Role of KS-Associated Herpesvirus in KS Pathogenesis.
Lidenge SJ; Tso FY; Ngalamika O; Ngowi JR; Mortazavi Y; Kwon EH; Shea DM; Minhas V; Mwaiselage J; Wood C; West JT
J Infect Dis; 2019 Apr; 219(8):1318-1328. PubMed ID: 30452681
[TBL] [Abstract][Full Text] [Related]
50. Recommendations for treating life-threatening Kaposi sarcoma during pregnancy in HIV-positive women in low income countries.
Bacha JM; El-Mallawany NK; Slone JS; Wilkinson JP; Mehta PS; Campbell LR
Int J STD AIDS; 2020 Jul; 31(8):724-734. PubMed ID: 32493141
[TBL] [Abstract][Full Text] [Related]
51. Longitudinal sero-reactivity to human herpesvirus 8 (KSHV) in the Swiss HIV Cohort 4.7 years before KS.
Quinlivan EB; Wang RX; Stewart PW; Kolmoltri C; Regamey N; Erb P; Vernazza PL;
J Med Virol; 2001 Jun; 64(2):157-66. PubMed ID: 11360248
[TBL] [Abstract][Full Text] [Related]
52. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphomas among HIV-1-infected individuals. Multicenter AIDS Cohort Study.
Jacobson LP; Yamashita TE; Detels R; Margolick JB; Chmiel JS; Kingsley LA; Melnick S; Muñoz A
J Acquir Immune Defic Syndr; 1999 Aug; 21 Suppl 1():S34-41. PubMed ID: 10430217
[TBL] [Abstract][Full Text] [Related]
53. Quantification of Kaposi's sarcoma-associated herpesvirus in blood, oral mucosa, and saliva in patients with Kaposi's sarcoma.
Marcelin AG; Gorin I; Morand P; Ait-Arkoub Z; Deleuze J; Morini JP; Calvez V; Dupin N
AIDS Res Hum Retroviruses; 2004 Jul; 20(7):704-8. PubMed ID: 15307914
[TBL] [Abstract][Full Text] [Related]
54. External validation of the Dat'AIDS score: A risk score for predicting 5-year overall mortality in people living with HIV aged 60 years or older.
Hentzien M; Frossard J; Kouyos R; Prendki V; Damas J; Hofmann E; Braun D; Schmid P; Bernasconi E; Ragozzino S; Efthimiou O; Delpierre C; Allavena C; Bani-Sadr F; Calmy A;
HIV Med; 2024 Jan; 25(1):72-82. PubMed ID: 37619609
[TBL] [Abstract][Full Text] [Related]
55. AIDS-related Kaposi's sarcoma in Brazil: trends and geopolitical distribution.
Saraceni V; Talhari CC; Pereira GF; Golub JE; Talhari S; Miranda AE
Int J Dermatol; 2013 Dec; 52(12):1525-9. PubMed ID: 24134514
[TBL] [Abstract][Full Text] [Related]
56. Detection and quantification of Kaposi's sarcoma-associated herpesvirus to predict AIDS-associated Kaposi's sarcoma.
Engels EA; Biggar RJ; Marshall VA; Walters MA; Gamache CJ; Whitby D; Goedert JJ
AIDS; 2003 Aug; 17(12):1847-51. PubMed ID: 12891072
[TBL] [Abstract][Full Text] [Related]
57. One hundred and five Kaposi sarcoma patients: a clinical study in Xinjiang, Northwest of China.
Wu XJ; Pu XM; Kang XJ; Halifu Y; An CX; Zhang DZ; Yakeya B; Mijit J
J Eur Acad Dermatol Venereol; 2014 Nov; 28(11):1545-52. PubMed ID: 25350316
[TBL] [Abstract][Full Text] [Related]
58. The clinical application of plasma Kaposi sarcoma herpesvirus viral load as a tumour biomarker: results from 704 patients.
Haq IU; Dalla Pria A; Papanastasopoulos P; Stegmann K; Bradshaw D; Nelson M; Bower M
HIV Med; 2016 Jan; 17(1):56-61. PubMed ID: 26111246
[TBL] [Abstract][Full Text] [Related]
59. KSHV viral load and Interleukin-6 in HIV-associated pediatric Kaposi sarcoma-Exploring the role of lytic activation in driving the unique clinical features seen in endemic regions.
El-Mallawany NK; Mehta PS; Kamiyango W; Villiera J; Peckham-Gregory EC; Kampani C; Krysiak R; Sanders MK; Caro-Vegas C; Eason AB; Ahmed S; Schutze GE; Martin SC; Kazembe PN; Scheurer ME; Dittmer DP
Int J Cancer; 2019 Jan; 144(1):110-116. PubMed ID: 30204240
[TBL] [Abstract][Full Text] [Related]
60. Effect of protease inhibitor-based highly active antiretroviral therapy on survival in HIV-associated advanced Kaposi's sarcoma patients treated with chemotherapy.
Leitch H; Trudeau M; Routy JP
HIV Clin Trials; 2003; 4(2):107-14. PubMed ID: 12671778
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
